We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Robert F. Kennedy Jr., who's nominated to become the next health secretary, asked the federal government to revoke its authorization of all COVID-19 vaccines in May 2021, just as vaccinated Americans ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Moderna (MRNA) stock surged 7% this week following Oracle (ORCL) CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure cancer.

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...